To assess whether low-dose 5-aza treatment can improve tumor immunogenicity, we evaluated changes in the IFN-γ signature score based on 6 genes known to be involved in IFN-γ pathway signaling (i.e., IDO1, CXCL10, CXCL9, HLA-DRA, STAT1, and IFNG) (7) and evaluated the change in expression of CD274 between paired baseline and on-treatment biopsies for individual participants. The gene discussed is IFNG; the disease is neoplasm.